Horizon Pharma Agrees to Buy Vidara Sending Shares Higher

Horizon Pharma Inc., maker of treatments for arthritis, pain and inflammatory diseases, agreed to purchase Ireland’s Vidara Therapeutics International Ltd. for about $660 million, sending shares to their highest value ever.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.